Searched for
DULOXETINE
Your foot pain could be more than just fatigue. Apollo doctor warns about two common but overlooked causesPersistent foot pain or burning can signal unstable blood sugar, often linked to diabetes or vitamin B12 deficiency. Diabetic neuropathy, c...- How clerk-turned-billionaire Ramprasad Reddy made Aurobindo a giant pharma companyRamprasad Reddy has his skin the game; he has made some timely bets with a nifty strategy for Aurobindo.
- Sensex climbs over 150 points, Nifty reclaims 10,200; Jet Airways cracks 4%Among Sensex stocks, Tata Motors rose 1.65 per cent, while Airtel added 1.49 per cent.
- Top stocks in focus on 08 December 2017Here is a list of top stocks that are likely to be in focus in today's trading session.
- need2know: 10 macro triggers that market would watch todayThe govt will bring in a law to penalise power distribution cos in the event of "gratuitous load-shedding.
- Lupin, Cadila recall drugs in US MarketZydus Pharmaceuticals USA Inc, arm of Cadila Healthcare, is also recalling 19,812 bottles of Paroxetine tablets in the strength of 30 mg fr...
- Lupin, Cadila Healthcare recall drugs in USZydus Pharmaceuticals USA Inc, arm of Cadila Healthcare, is also recalling 19,812 bottles of Paroxetine tablets in the strength of 30 mg fr...
- Eleven stocks in focus on Tuesday, 10 January 2017State-run Bank of Baroda on Monday reduced home loan rates by 70 basis points to the industry's lowest level of 8.35 per cent that will be ...
- Sensex drops over 500 points, Nifty below 7,700; Amtek Auto plunges 12%, Cipla up 3%The S&P BSE Sensex plunged over 200 points in trade on Friday tracking muted trend seen in other Asian markets. The fall in the index was l...
- Fourteen stocks in focus in Friday's tradeIndian markets are expected to trade in a range. Here is a list of fourteen stocks which are likely to remain in focus today.
- Lupin launches 40 mg Duloxetine DR capsules in the USLupin is now the only generic manufacturer to offer all Duloxetine dosage strengths - the 20 mg, 30 mg, 60 mg, and now the newest 40 mg.
- Sun Pharma slumps after Q1 net profit fallsA drop in US sales and the integration of Ranbaxy Laboratories weighed on the financial performance of nation's top drug maker.
- Slowdown in US sales, Ranbaxy integration weigh on Sun PharmaIn the past quarter, Sun’s R&D expense was Rs 511 crore. It filed for six new drugs in US and so far received approvals for four.
- More steam left in small & midcap stocks; top 5 bets which can give up to 26% return in next 6-24 months: Bonanza"With GDP bottoming out and reduction in interest rates in India, we are headed for a massive rally ahead," says Yogesh Nagaonkar of Bonanz...
- Dr Reddy's Lab launches duloxetine delayed-release capsulesCymbalata (duloxetine delayed- release capsules) brand and generic had US sales of $5.04 billion for the most recent 12 months ending April...
- Zydus Cadila gets USFDA nod to sell drugs in the US market"Zydus Cadila received the final approval from the USFDA to market Sirolimus tablets 0.5 mg with 180 days of marketing exclusivity,"
- Sun Pharma gets USFDA nod for anti-depressant drugThe company said its subsidiary has received nod from the US Food and Drug Administration to market Duloxetine Delayed-Release Capsules.
- Several Indian companies get FDA nod for anti-depressant drugThe US Food and Drug Administration has approved the first generic versions of Cymbalta, a prescription medicine used in treatment of depre...
- Wockhardt gets USFDA tentative nod to sell anti-depressantDrug firm Wockhardt said it has received tentative approval from USFDA to market generic Duloxetine Hydrochloride capsules, used for treati...
- Wockhardt get tentative nod from USFDA for Duloxetine, stk upWockhardt has received tentative approval from the USFDA for Duloxetine, a generic version of depression drug Cymbalta.
Load More
